Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jean-Claude Makenga Bof"'
Autor:
Jean-Claude Makenga Bof, Daniel Muteba, Paul Mansiangi, Félicien Ilunga-Ilunga, Yves Coppieters
Publikováno v:
BMC Pharmacology and Toxicology, Vol 20, Iss 1, Pp 1-10 (2019)
Abstract Background The progress of mass, community-directed, treatment with ivermectin (CDTI) for onchocerciasis control was disrupted by severe adverse effects (SAE) in the Democratic Republic of Congo (DRC). The study aimed at determining the freq
Externí odkaz:
https://doaj.org/article/9b3646f88d074417a97e403262bd200c
Autor:
Jean-Claude Makenga Bof, Dieudonne Mpunga, Emery N. Soa, Fortunat Ntumba, Didier Bakajika, Michele E. Murdoch, Yves Coppieters
Publikováno v:
Journal of Infection and Public Health, Vol 10, Iss 5, Pp 600-607 (2017)
A community-directed treatment with ivermectin (CDTI) for fighting onchocerciasis was started in 2003 in the hyperendemic province of Bandundu, Democratic Republic of Congo (DRC); such initiative was supported by the African Programme for Onchocercia
Externí odkaz:
https://doaj.org/article/c7c3390ecc484dd981045119f670ea01
Autor:
Jean-Claude Makenga Bof, Paul Mansiangi, Horlyne Nsangi, Éric Mafuta, Isabelle Aujoulat, Yves Coppieters
Publikováno v:
Tropical Medicine and Infectious Disease, Vol 4, Iss 3, p 109 (2019)
The success of community-directed treatment with Ivermectin (CDTI) depends on active community participation. We conducted a case study nested in a cross-sectional study in the Binza Ozone Health Zone (ZS) in Kinshasa, Democratic Republic of Congo, i
Externí odkaz:
https://doaj.org/article/6fe9d2dd4a7145dd9aa90e5d4eff0f12
Autor:
Jean-Claude Makenga Bof, Fortunat Ntumba Tshitoka, Daniel Muteba, Paul Mansiangi, Yves Coppieters
Publikováno v:
Tropical Medicine and Infectious Disease, Vol 4, Iss 2, p 92 (2019)
Here, we review all data available at the Ministry of Public Health in order to describe the history of the National Program for Onchocerciasis Control (NPOC) in the Democratic Republic of the Congo (DRC). Discovered in 1903, the disease is endemic i
Externí odkaz:
https://doaj.org/article/d8d750b17527488890e0f8fcd24042b0
Background Onchocerciasis, a parasitic disease caused by the filarial worm Onchocerca volvulus transmitted through the bite of Simulium (black flies), is a cause of global concern, with the African population being majorly affected. This study focuse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cf8e328e20d057a17a4270414273fbf
https://doi.org/10.21203/rs.3.rs-437321/v1
https://doi.org/10.21203/rs.3.rs-437321/v1
Autor:
Michele Me Murdoch, Fortunat F Ntumba, Didier D Bakajika, Emery En Soa, Dieudonne D Mpunga, Yves Coppieters, Jean-Claude Makenga Bof
Publikováno v:
Journal of Infection and Public Health, Vol 10, Iss 5, Pp 600-607 (2017)
Journal of Infection and Public Health, 16 (pii: S1876-0341(17)30052-7.
Journal of Infection and Public Health, 16 (pii: S1876-0341(17)30052-7.
A community-directed treatment with ivermectin (CDTI) for fighting onchocerciasis was started in 2003 in the hyperendemic province of Bandundu, Democratic Republic of Congo (DRC); such initiative was supported by the African Programme for Onchocercia
Autor:
Yves Coppieters, Félicien Ilunga-Ilunga, Daniel Muteba, Paul Mansiangi, Jean-Claude Makenga Bof
Publikováno v:
BMC Pharmacology and Toxicology, 20 (1
BMC Pharmacology and Toxicology, Vol 20, Iss 1, Pp 1-10 (2019)
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 20, Iss 1, Pp 1-10 (2019)
BMC Pharmacology & Toxicology
The progress of mass, community-directed, treatment with ivermectin (CDTI) for onchocerciasis control was disrupted by severe adverse effects (SAE) in the Democratic Republic of Congo (DRC). The study aimed at determining the frequency of post-CDTI S
Autor:
Jack Hyyombo Tambwe Kokolomami, Aimee Lulebo Mampasi, Paul Mansiangi Mankadi, Jean Nyandwe, Guillaume Kiyombo Mbela, Jean-Claude Makenga Bof
Publikováno v:
Central African Journal of Public Health. 6:13
Health Workers (HWs) are most likely to be infected by the Ebola virus disease (EVD) through mainly nosocomial transmission because they treat patients with EVD; this occurs through close contact with patients when infection prevention and control (I